These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 25751578)

  • 1. A randomized, placebo-controlled trial of the analgesic efficacy and safety of the p38 MAP kinase inhibitor, losmapimod, in patients with neuropathic pain from lumbosacral radiculopathy.
    Ostenfeld T; Krishen A; Lai RY; Bullman J; Green J; Anand P; Scholz J; Kelly M
    Clin J Pain; 2015 Apr; 31(4):283-93. PubMed ID: 25751578
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analgesic efficacy and safety of the novel p38 MAP kinase inhibitor, losmapimod, in patients with neuropathic pain following peripheral nerve injury: a double-blind, placebo-controlled study.
    Ostenfeld T; Krishen A; Lai RY; Bullman J; Baines AJ; Green J; Anand P; Kelly M
    Eur J Pain; 2013 Jul; 17(6):844-57. PubMed ID: 23239139
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of the p38 MAPK inhibitor losmapimod for patients with chronic obstructive pulmonary disease: a randomised, double-blind, placebo-controlled trial.
    Watz H; Barnacle H; Hartley BF; Chan R
    Lancet Respir Med; 2014 Jan; 2(1):63-72. PubMed ID: 24461903
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of antidepressant properties of the p38 MAP kinase inhibitor losmapimod (GW856553) in Major Depressive Disorder: Results from two randomised, placebo-controlled, double-blind, multicentre studies using a Bayesian approach.
    Inamdar A; Merlo-Pich E; Gee M; Makumi C; Mistry P; Robertson J; Steinberg E; Zamuner S; Learned S; Alexander R; Ratti E
    J Psychopharmacol; 2014 Jun; 28(6):570-81. PubMed ID: 24699061
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Double-blind, placebo-controlled trial of lamotrigine in combination with other medications for neuropathic pain.
    Silver M; Blum D; Grainger J; Hammer AE; Quessy S
    J Pain Symptom Manage; 2007 Oct; 34(4):446-54. PubMed ID: 17662571
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of Losmapimod on Cardiovascular Outcomes in Patients Hospitalized With Acute Myocardial Infarction: A Randomized Clinical Trial.
    O'Donoghue ML; Glaser R; Cavender MA; Aylward PE; Bonaca MP; Budaj A; Davies RY; Dellborg M; Fox KA; Gutierrez JA; Hamm C; Kiss RG; Kovar F; Kuder JF; Im KA; Lepore JJ; Lopez-Sendon JL; Ophuis TO; Parkhomenko A; Shannon JB; Spinar J; Tanguay JF; Ruda M; Steg PG; Theroux P; Wiviott SD; Laws I; Sabatine MS; Morrow DA;
    JAMA; 2016 Apr; 315(15):1591-9. PubMed ID: 27043082
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and tolerability of pregabalin using a flexible, optimized dose schedule in Korean patients with peripheral neuropathic pain: a 10-week, randomized, double-blind, placebo-controlled, multicenter study.
    Moon DE; Lee DI; Lee SC; Song SO; Yoon DM; Yoon MH; Kim HK; Lee YW; Kim C; Lee PB
    Clin Ther; 2010 Dec; 32(14):2370-85. PubMed ID: 21353106
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of pregabalin for peripheral neuropathic pain: results of an 8-week, flexible-dose, double-blind, placebo-controlled study conducted in China.
    Guan Y; Ding X; Cheng Y; Fan D; Tan L; Wang Y; Zhao Z; Hong Z; Zhou D; Pan X; Chen S; Martin A; Tang H; Cui L
    Clin Ther; 2011 Feb; 33(2):159-66. PubMed ID: 21444113
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized, double-blind, placebo-controlled trial and open-label extension study to evaluate the efficacy and safety of pregabalin in the treatment of neuropathic pain associated with human immunodeficiency virus neuropathy.
    Simpson DM; Rice AS; Emir B; Landen J; Semel D; Chew ML; Sporn J
    Pain; 2014 Oct; 155(10):1943-54. PubMed ID: 24907403
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical trial of the p38 MAP kinase inhibitor dilmapimod in neuropathic pain following nerve injury.
    Anand P; Shenoy R; Palmer JE; Baines AJ; Lai RY; Robertson J; Bird N; Ostenfeld T; Chizh BA
    Eur J Pain; 2011 Nov; 15(10):1040-8. PubMed ID: 21576029
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rationale and design of the LosmApimod To Inhibit p38 MAP kinase as a TherapeUtic target and moDify outcomes after an acute coronary syndromE trial.
    O'Donoghue ML; Glaser R; Aylward PE; Cavender MA; Crisp A; Fox KA; Laws I; Lopez-Sendon JL; Steg PG; Theroux P; Sabatine MS; Morrow DA
    Am Heart J; 2015 May; 169(5):622-630.e6. PubMed ID: 25965709
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fentanyl buccal tablet for the relief of breakthrough pain in opioid-tolerant adult patients with chronic neuropathic pain: a multicenter, randomized, double-blind, placebo-controlled study.
    Simpson DM; Messina J; Xie F; Hale M
    Clin Ther; 2007 Apr; 29(4):588-601. PubMed ID: 17617282
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A double-blind, randomized, placebo-controlled, parallel group study of THC/CBD spray in peripheral neuropathic pain treatment.
    Serpell M; Ratcliffe S; Hovorka J; Schofield M; Taylor L; Lauder H; Ehler E
    Eur J Pain; 2014 Aug; 18(7):999-1012. PubMed ID: 24420962
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Phase II Randomized, Double-Blind, Placebo-Controlled Safety and Efficacy Study of Lenalidomide in Lumbar Radicular Pain with a Long-Term Open-Label Extension Phase.
    Manning DC; Gimbel J; Wertz R; Rauck R; Cooper A; Zeldis JB; Levinsky DM
    Pain Med; 2017 Mar; 18(3):477-487. PubMed ID: 27550953
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A post-hoc subgroup analysis of data from a six month clinical trial comparing the efficacy and safety of losmapimod in moderate-severe COPD patients with ≤2% and >2% blood eosinophils.
    Marks-Konczalik J; Costa M; Robertson J; McKie E; Yang S; Pascoe S
    Respir Med; 2015 Jul; 109(7):860-9. PubMed ID: 26033641
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of minocycline on lumbar radicular neuropathic pain: a randomized, placebo-controlled, double-blind clinical trial with amitriptyline as a comparator.
    Vanelderen P; Van Zundert J; Kozicz T; Puylaert M; De Vooght P; Mestrum R; Heylen R; Roubos E; Vissers K
    Anesthesiology; 2015 Feb; 122(2):399-406. PubMed ID: 25373391
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and efficacy of losmapimod in facioscapulohumeral muscular dystrophy (ReDUX4): a randomised, double-blind, placebo-controlled phase 2b trial.
    Tawil R; Wagner KR; Hamel JI; Leung DG; Statland JM; Wang LH; Genge A; Sacconi S; Lochmüller H; Reyes-Leiva D; Diaz-Manera J; Alonso-Perez J; Muelas N; Vilchez JJ; Pestronk A; Gibson S; Goyal NA; Hayward LJ; Johnson N; LoRusso S; Freimer M; Shieh PB; Subramony SH; van Engelen B; Kools J; Leinhard OD; Widholm P; Morabito C; Moxham CM; Cadavid D; Mellion ML; Odueyungbo A; Tracewell WG; Accorsi A; Ronco L; Gould RJ; Shoskes J; Rojas LA; Jiang JG
    Lancet Neurol; 2024 May; 23(5):477-486. PubMed ID: 38631764
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pregabalin for peripheral neuropathic pain: a multicenter, enriched enrollment randomized withdrawal placebo-controlled trial.
    Gilron I; Wajsbrot D; Therrien F; Lemay J
    Clin J Pain; 2011; 27(3):185-93. PubMed ID: 21178603
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A 2-week, multicenter, randomized, double-blind, placebo-controlled, dose-ranging, phase III trial comparing the efficacy of oxymorphone extended release and placebo in adults with pain associated with osteoarthritis of the hip or knee.
    Kivitz A; Ma C; Ahdieh H; Galer BS
    Clin Ther; 2006 Mar; 28(3):352-64. PubMed ID: 16750450
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pregabalin in central neuropathic pain associated with spinal cord injury: a placebo-controlled trial.
    Siddall PJ; Cousins MJ; Otte A; Griesing T; Chambers R; Murphy TK
    Neurology; 2006 Nov; 67(10):1792-800. PubMed ID: 17130411
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.